Endothelial and platelet microparticles in patients with antiphospholipid antibodies

被引：43

作者：

Breen, K. A. ^{[1
]}

Sanchez, K. ^{[2
]}

Kirkman, N. ^{[2
]}

Seed, P. T. ^{[3
]}

Parmar, K. ^{[1
]}

Moore, G. W. ^{[2
]}

Hunt, B. J. ^{[1
,3
]}

机构：

[1] Guys & St Thomas NHS Fdn Trust, London, England

[2] Guys & St Thomas NHS Fdn Trust, London, England

[3] Kings Coll London, London WC2R 2LS, England

来源：

THROMBOSIS RESEARCH | 2015年 / 135卷 / 02期

关键词：

Antiphospholipid antibodies; Antiphospholipid syndrome; Microparticles; CIRCULATING PROCOAGULANT MICROPARTICLES; SYSTEMIC-LUPUS-ERYTHEMATOSUS; FLOW-CYTOMETRY; PLASMA-MEMBRANE; IN-VITRO; ACTIVATION; CELLS; COMPLEMENT; VESICULATION; ASSOCIATION;

D O I：

10.1016/j.thromres.2014.11.027

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Background: The antiphospholipid syndrome (APS) is the association of thrombosis and recurrent pregnancy loss and/or pregnancy morbidity with persistent antiphospholipid antibodies (aPL). Previous studies of microparticles in patients with APS/aPL have mainly been small and findings, contradictory. Objectives: To quantify endothelial and platelet microparticle levels in patients with isolated antiphospholipid antibodies or primary antiphospholipid syndrome (PAPS). Patients/Methods: We measured endothelial and platelet microparticle levels by flow cytometry in 66 aPL/PAPS patients and 18 healthy controls. Results: Levels of circulating platelet (CD41 and CD61) and endothelial microparticles (CD51 and CD105) were significantly increased in patients with PAPS and aPL compared to healthy controls. There were correlations between platelet and endothelial microparticles levels in all patients with aPL. Conclusions: Platelet and endothelial microparticles are increased in all patient groups within this cohort of patients aPL. Whether they may have a role in the pathogenesis of APS merits further study. (C) 2014 Elsevier Ltd. All rights reserved.

引用

页码：368 / 374

页数：7

共 53 条

[1] Contribution of Complement Component C3 and Complement Receptor Type 3 to Carbohydrate-dependent Uptake of Oligomannose-coated Liposomes by Peritoneal Macrophages [J].